A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
The study will examine how safe and effective apricitabine is when given long term (as
 ongoing treatment) to HIV patients who have already completed the AVX-201 trial
An ongoing study (AVX-201) is examining the safety and efficacy of apricitabine compared to
 3TC in HIV patients who are failing therapy containing 3TC and have the presence of the M184V
 mutation in reverse transcriptase. This extension study (AVX-201E) is available to patients
 who complete the AVX-201 protocol.

 Patients will continue to receive apricitabine open label for a further 96 weeks (making a
 total of 144 weeks from starting AVX-201) in addition to an optimised background. Safety
 markers and efficacy markers will be followed.
Inclusion Criteria:

 -  Completed AVX-201 protocol, Plasma HIV RNA <5000 copies/ml, CD4 cells >50

 Exclusion Criteria:

 -  Pregnant or breastfeeding females, withdrawal from AVX-201